Skip to main content
. 2022 Nov 29;14(12):2641. doi: 10.3390/pharmaceutics14122641

Figure 4.

Figure 4

(a) Biodistribution of the nanoMOFs in vivo at different times after tail vein injection. (b) The percentage of excretion of nanoMOFs at different times after tail vein injection. Reproduced from Ref. [114] with permission from Wiley–VCH, copyright 2019.